BASKING RIDGE, N.J.
Aug. 21, 2013
/PRNewswire/ -- Regado Biosciences, Inc., today announced the pricing of its initial public offering of 10,750,000 shares of its common stock at a price to the public of
per share, before underwriting discounts. All of the common stock is being offered by Regado Biosciences. In addition, Regado Biosciences has granted the underwriters a 30-day option to purchase up to an additional 925,000 shares of common stock at the initial public offering price to cover over-allotments, if any, at the initial public offering price. The shares are scheduled to begin trading on the NASDAQ Capital Market on
August 22, 2013
under the ticker symbol "RGDO." The offering is expected to close on
August 27, 2013
, subject to customary closing conditions.
Cowen and Company, LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Canaccord Genuity Inc., Needham & Company, LLC, and Wedbush PacGrow Life Sciences are acting as co-managers. The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
, NY,11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square,
New York, NY
10036, Telephone: (800) 414-3627, Email:
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on
, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. The actively controllable product candidates have the potential to improve outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at
Tiberend Strategic Advisors, Inc.
; (212) 375-2664
; (212) 375-2694
SOURCE Regado Biosciences, Inc.